Cyamemazine

Explore a selection of our essential drug information below, or:

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Generic Name

Cyamemazine

DrugBank Accession Number

DB09000

Background

Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).

Type

Small Molecule

Groups

Experimental

Structure

Similar Structures

Weight: Average: 323.455
Monoisotopic: 323.145618377
Chemical Formula: C₁₉H₂₁N₃S

Synonyms

Cyamemazine

Poor quality drug data slowing you down?

Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.

Download eBook

Poor quality drug data slowing you down?

Download eBook

Pharmacology

Indication: Not Available
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings: Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Integrate drug-drug interactions in your software
1,2-Benzodiazepine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with 1,2-Benzodiazepine.
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Cyamemazine.
Acetazolamide	The risk or severity of CNS depression can be increased when Acetazolamide is combined with Cyamemazine.
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Cyamemazine.
Acetophenazine	The risk or severity of CNS depression can be increased when Acetophenazine is combined with Cyamemazine.
Agomelatine	The risk or severity of CNS depression can be increased when Agomelatine is combined with Cyamemazine.
Alfentanil	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Alfentanil.
Alimemazine	The risk or severity of CNS depression can be increased when Alimemazine is combined with Cyamemazine.
Almasilate	Almasilate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Almotriptan	The risk or severity of adverse effects can be increased when Almotriptan is combined with Cyamemazine.
Alosetron	The risk or severity of CNS depression can be increased when Alosetron is combined with Cyamemazine.
Alprazolam	The risk or severity of CNS depression can be increased when Alprazolam is combined with Cyamemazine.
Aluminium	Aluminium can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphate	Aluminium phosphate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxide	Aluminum hydroxide can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alverine	The risk or severity of CNS depression can be increased when Alverine is combined with Cyamemazine.
Amisulpride	Cyamemazine may increase the antipsychotic activities of Amisulpride.
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Cyamemazine.
Amitriptylinoxide	The serum concentration of Amitriptylinoxide can be increased when it is combined with Cyamemazine.
Amobarbital	The risk or severity of CNS depression can be increased when Amobarbital is combined with Cyamemazine.
Amodiaquine	The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Cyamemazine.
Amoxapine	The serum concentration of Amoxapine can be increased when it is combined with Cyamemazine.
Amphetamine	Cyamemazine may decrease the stimulatory activities of Amphetamine.
Apomorphine	The risk or severity of CNS depression can be increased when Apomorphine is combined with Cyamemazine.
Apronalide	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Apronalide.
Aripiprazole	The risk or severity of CNS depression can be increased when Aripiprazole is combined with Cyamemazine.
Aripiprazole lauroxil	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Aripiprazole lauroxil.
Artemether	The risk or severity of QTc prolongation can be increased when Artemether is combined with Cyamemazine.
Artemotil	The risk or severity of QTc prolongation can be increased when Artemotil is combined with Cyamemazine.
Artenimol	The risk or severity of QTc prolongation can be increased when Artenimol is combined with Cyamemazine.
Artesunate	The risk or severity of QTc prolongation can be increased when Artesunate is combined with Cyamemazine.
Articaine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Articaine.
Asenapine	The risk or severity of CNS depression can be increased when Asenapine is combined with Cyamemazine.
Atenolol	The serum concentration of Atenolol can be increased when it is combined with Cyamemazine.
Atovaquone	The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Cyamemazine.
Atracurium	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Atracurium.
Atracurium besylate	The risk or severity of CNS depression can be increased when Atracurium besylate is combined with Cyamemazine.
Azelastine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Baclofen	Baclofen may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Benperidol	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Benperidol.
Benzhydrocodone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Benzhydrocodone.
Benzocaine	The risk or severity of CNS depression can be increased when Benzocaine is combined with Cyamemazine.
Benzphetamine	Cyamemazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcohol	The risk or severity of CNS depression can be increased when Benzyl alcohol is combined with Cyamemazine.
Betaxolol	The serum concentration of Betaxolol can be increased when it is combined with Cyamemazine.
Bismuth subcitrate potassium	Cyamemazine may increase the neurotoxic activities of Bismuth subcitrate potassium.
Bismuth subgallate	Cyamemazine may increase the neurotoxic activities of Bismuth subgallate.
Bismuth subnitrate	Bismuth subnitrate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisoprolol	The serum concentration of Bisoprolol can be increased when it is combined with Cyamemazine.
Botulinum toxin type A	The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Cyamemazine.
Botulinum toxin type B	The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Cyamemazine.
Brexanolone	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Brexanolone.
Brexpiprazole	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Brexpiprazole.
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Brivaracetam	The risk or severity of CNS depression can be increased when Brivaracetam is combined with Cyamemazine.
Bromazepam	The risk or severity of CNS depression can be increased when Bromazepam is combined with Cyamemazine.
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Cyamemazine.
Bromperidol	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Bromperidol.
Brompheniramine	The risk or severity of CNS depression can be increased when Brompheniramine is combined with Cyamemazine.
Bupivacaine	The risk or severity of CNS depression can be increased when Bupivacaine is combined with Cyamemazine.
Buprenorphine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion	The risk or severity of CNS depression can be increased when Bupropion is combined with Cyamemazine.
Buspirone	The risk or severity of CNS depression can be increased when Buspirone is combined with Cyamemazine.
Butabarbital	The risk or severity of CNS depression can be increased when Butabarbital is combined with Cyamemazine.
Butalbital	The risk or severity of CNS depression can be increased when Butalbital is combined with Cyamemazine.
Butaperazine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Butaperazine.
Butobarbital	The risk or severity of CNS depression can be increased when Butobarbital is combined with Cyamemazine.
Butorphanol	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Butorphanol.
Butriptyline	The serum concentration of Butriptyline can be increased when it is combined with Cyamemazine.
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Cyamemazine.
Calcium carbonate	Calcium carbonate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cannabidiol	The risk or severity of adverse effects can be increased when Cannabidiol is combined with Cyamemazine.
Carbamazepine	The risk or severity of CNS depression can be increased when Carbamazepine is combined with Cyamemazine.
Carbinoxamine	The risk or severity of CNS depression can be increased when Carbinoxamine is combined with Cyamemazine.
Cariprazine	The risk or severity of CNS depression can be increased when Cariprazine is combined with Cyamemazine.
Carisoprodol	The risk or severity of adverse effects can be increased when Carisoprodol is combined with Cyamemazine.
Carvedilol	The serum concentration of Carvedilol can be increased when it is combined with Cyamemazine.
Celiprolol	The serum concentration of Celiprolol can be increased when it is combined with Cyamemazine.
Cetirizine	The risk or severity of CNS depression can be increased when Cetirizine is combined with Cyamemazine.
Chloral hydrate	The risk or severity of CNS depression can be increased when Chloral hydrate is combined with Cyamemazine.
Chlordiazepoxide	The risk or severity of CNS depression can be increased when Chlordiazepoxide is combined with Cyamemazine.
Chlormezanone	The risk or severity of CNS depression can be increased when Chlormezanone is combined with Cyamemazine.
Chloroprocaine	The risk or severity of CNS depression can be increased when Chloroprocaine is combined with Cyamemazine.
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Cyamemazine.
Chlorpheniramine	The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Cyamemazine.
Chlorpromazine	The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Cyamemazine.
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Cyamemazine.
Chlorprothixene	The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Cyamemazine.
Chlorzoxazone	The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Cyamemazine.
Cinchocaine	The risk or severity of CNS depression can be increased when Cinchocaine is combined with Cyamemazine.
Cisapride	The risk or severity of CNS depression can be increased when Cisapride is combined with Cyamemazine.
Cisatracurium	The risk or severity of CNS depression can be increased when Cisatracurium is combined with Cyamemazine.
Citalopram	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Citalopram.
Clemastine	The risk or severity of CNS depression can be increased when Clemastine is combined with Cyamemazine.
Clidinium	The risk or severity of CNS depression can be increased when Clidinium is combined with Cyamemazine.
Clindamycin	Clindamycin may increase the neurotoxic activities of Cyamemazine.
Clobazam	The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Cyamemazine.
Clomipramine	The serum concentration of desmethylclomipramine, an active metabolite of Clomipramine, can be increased when used in combination with Cyamemazine.
Clonazepam	The risk or severity of CNS depression can be increased when Clonazepam is combined with Cyamemazine.
Clonidine	The risk or severity of sedation can be increased when Clonidine is combined with Cyamemazine.
Clorazepic acid	The risk or severity of CNS depression can be increased when Clorazepic acid is combined with Cyamemazine.
Clothiapine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Clothiapine.
Clotiazepam	The risk or severity of CNS depression can be increased when Clotiazepam is combined with Cyamemazine.
Clozapine	The risk or severity of CNS depression can be increased when Clozapine is combined with Cyamemazine.
Codeine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Codeine.
Cyclizine	The risk or severity of CNS depression can be increased when Cyclizine is combined with Cyamemazine.
Cyclobenzaprine	The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Cyamemazine.
Cycloguanil	The risk or severity of QTc prolongation can be increased when Cycloguanil is combined with Cyamemazine.
Cyclophosphamide	Cyclophosphamide may increase the neurotoxic activities of Cyamemazine.
Cycloserine	Cycloserine may increase the neurotoxic activities of Cyamemazine.
Cyclosporine	Cyclosporine may increase the neurotoxic activities of Cyamemazine.
Cyproheptadine	The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Cyamemazine.
Dantrolene	The risk or severity of CNS depression can be increased when Dantrolene is combined with Cyamemazine.
Dapsone	The risk or severity of QTc prolongation can be increased when Dapsone is combined with Cyamemazine.
Daridorexant	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Daridorexant.
Decamethonium	The risk or severity of CNS depression can be increased when Decamethonium is combined with Cyamemazine.
Desflurane	The risk or severity of CNS depression can be increased when Desflurane is combined with Cyamemazine.
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Cyamemazine.
Desloratadine	The risk or severity of CNS depression can be increased when Desloratadine is combined with Cyamemazine.
Desvenlafaxine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Desvenlafaxine.
Deutetrabenazine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Deutetrabenazine.
Dexbrompheniramine	The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Cyamemazine.
Dexmedetomidine	The risk or severity of CNS depression can be increased when Dexmedetomidine is combined with Cyamemazine.
Dexmethylphenidate	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Dexmethylphenidate.
Dextroamphetamine	Cyamemazine may decrease the stimulatory activities of Dextroamphetamine.
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyamemazine.
Dextropropoxyphene	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Dextropropoxyphene.
Dezocine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Dezocine.
Diamorphine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Diamorphine.
Diazepam	The risk or severity of CNS depression can be increased when Diazepam is combined with Cyamemazine.
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Cyamemazine.
Dichloralphenazone	The risk or severity of CNS depression can be increased when Dichloralphenazone is combined with Cyamemazine.
Didanosine	Didanosine may increase the neurotoxic activities of Cyamemazine.
Diethylpropion	Cyamemazine may decrease the stimulatory activities of Diethylpropion.
Difenoxin	The risk or severity of CNS depression can be increased when Difenoxin is combined with Cyamemazine.
Dihydrocodeine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Dihydrocodeine.
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyamemazine.
Dimenhydrinate	The risk or severity of CNS depression can be increased when Dimenhydrinate is combined with Cyamemazine.
Diphenhydramine	The risk or severity of CNS depression can be increased when Diphenhydramine is combined with Cyamemazine.
Diphenoxylate	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Diphenoxylate.
Dolasetron	The risk or severity of CNS depression can be increased when Dolasetron is combined with Cyamemazine.
Donepezil	The risk or severity of CNS depression can be increased when Donepezil is combined with Cyamemazine.
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Cyamemazine.
Doxacurium	The risk or severity of CNS depression can be increased when Doxacurium is combined with Cyamemazine.
Doxepin	The serum concentration of Doxepin can be increased when it is combined with Cyamemazine.
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Duloxetine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Duloxetine.
Dyclonine	The risk or severity of CNS depression can be increased when Dyclonine is combined with Cyamemazine.
Efavirenz	The risk or severity of CNS depression can be increased when Efavirenz is combined with Cyamemazine.
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Cyamemazine.
Eluxadoline	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Eluxadoline.
Enflurane	The risk or severity of CNS depression can be increased when Enflurane is combined with Cyamemazine.
Entacapone	The risk or severity of CNS depression can be increased when Entacapone is combined with Cyamemazine.
Epinastine	The risk or severity of CNS depression can be increased when Epinastine is combined with Cyamemazine.
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Cyamemazine.
Ergometrine	The risk or severity of adverse effects can be increased when Ergometrine is combined with Cyamemazine.
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Cyamemazine.
Escitalopram	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Escitalopram.
Esketamine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Esketamine.
Eslicarbazepine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Eslicarbazepine.
Eslicarbazepine acetate	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Eslicarbazepine acetate.
Esmolol	The serum concentration of Esmolol can be increased when it is combined with Cyamemazine.
Estazolam	The risk or severity of CNS depression can be increased when Estazolam is combined with Cyamemazine.
Eszopiclone	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Eszopiclone.
Ethanol	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol	The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Cyamemazine.
Ethosuximide	The risk or severity of CNS depression can be increased when Ethosuximide is combined with Cyamemazine.
Ethotoin	The risk or severity of CNS depression can be increased when Ethotoin is combined with Cyamemazine.
Etomidate	The risk or severity of CNS depression can be increased when Etomidate is combined with Cyamemazine.
Ezogabine	The risk or severity of CNS depression can be increased when Ezogabine is combined with Cyamemazine.
Felbamate	The risk or severity of CNS depression can be increased when Felbamate is combined with Cyamemazine.
Fenfluramine	The risk or severity of CNS depression can be increased when Fenfluramine is combined with Cyamemazine.
Fentanyl	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Fentanyl.
Flibanserin	The risk or severity of CNS depression can be increased when Flibanserin is combined with Cyamemazine.
Flunarizine	The risk or severity of CNS depression can be increased when Flunarizine is combined with Cyamemazine.
Flunitrazepam	The risk or severity of CNS depression can be increased when Flunitrazepam is combined with Cyamemazine.
Fluoxetine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.
Flupentixol	The risk or severity of CNS depression can be increased when Flupentixol is combined with Cyamemazine.
Fluphenazine	The risk or severity of CNS depression can be increased when Fluphenazine is combined with Cyamemazine.
Flurazepam	The risk or severity of CNS depression can be increased when Flurazepam is combined with Cyamemazine.
Fluspirilene	The risk or severity of CNS depression can be increased when Fluspirilene is combined with Cyamemazine.
Fluticasone propionate	The risk or severity of CNS depression can be increased when Fluticasone propionate is combined with Cyamemazine.
Fluvoxamine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Fluvoxamine.
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Cyamemazine.
Fospropofol	The risk or severity of CNS depression can be increased when Fospropofol is combined with Cyamemazine.
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Cyamemazine.
Gabapentin	The risk or severity of CNS depression can be increased when Gabapentin is combined with Cyamemazine.
Gabapentin enacarbil	The risk or severity of CNS depression can be increased when Gabapentin enacarbil is combined with Cyamemazine.
Gallamine triethiodide	The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Cyamemazine.
gamma-Hydroxybutyric acid	The risk or severity of CNS depression can be increased when gamma-Hydroxybutyric acid is combined with Cyamemazine.
Ganaxolone	The risk or severity of sedation, somnolence, and CNS depression can be increased when Cyamemazine is combined with Ganaxolone.
Gepirone	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Gepirone.
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Cyamemazine.
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Cyamemazine.
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Cyamemazine.
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Cyamemazine.
Glutethimide	The risk or severity of CNS depression can be increased when Glutethimide is combined with Cyamemazine.
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Cyamemazine.
Granisetron	The risk or severity of CNS depression can be increased when Granisetron is combined with Cyamemazine.
Guanfacine	The risk or severity of CNS depression can be increased when Guanfacine is combined with Cyamemazine.
Halazepam	The risk or severity of CNS depression can be increased when Halazepam is combined with Cyamemazine.
Halofantrine	The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Cyamemazine.
Haloperidol	The risk or severity of CNS depression can be increased when Haloperidol is combined with Cyamemazine.
Halothane	The risk or severity of CNS depression can be increased when Halothane is combined with Cyamemazine.
Hexafluronium	The risk or severity of CNS depression can be increased when Hexafluronium is combined with Cyamemazine.
Hydrocodone	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydromorphone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Hydromorphone.
Hydrotalcite	Hydrotalcite can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hydroxychloroquine	The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Cyamemazine.
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Hyoscyamine	Cyamemazine may increase the anticholinergic activities of Hyoscyamine.
Iloperidone	The risk or severity of CNS depression can be increased when Iloperidone is combined with Cyamemazine.
Imipenem	Imipenem may increase the neurotoxic activities of Cyamemazine.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Cyamemazine.
Insulin aspart	The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Cyamemazine.
Insulin beef	The therapeutic efficacy of Insulin beef can be decreased when used in combination with Cyamemazine.
Insulin degludec	The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Cyamemazine.
Insulin detemir	The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Cyamemazine.
Insulin glargine	The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Cyamemazine.
Insulin glulisine	The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Cyamemazine.
Insulin human	The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyamemazine.
Insulin lispro	The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Cyamemazine.
Insulin pork	The therapeutic efficacy of Insulin pork can be decreased when used in combination with Cyamemazine.
Iofetamine I-123	Cyamemazine may decrease the stimulatory activities of Iofetamine I-123.
Isocarboxazid	The risk or severity of extrapyramidal symptoms can be increased when Isocarboxazid is combined with Cyamemazine.
Isoflurane	The risk or severity of CNS depression can be increased when Isoflurane is combined with Cyamemazine.
Ketamine	The risk or severity of CNS depression can be increased when Ketamine is combined with Cyamemazine.
Ketazolam	The risk or severity of CNS depression can be increased when Ketazolam is combined with Cyamemazine.
Labetalol	The serum concentration of Labetalol can be increased when it is combined with Cyamemazine.
Lamotrigine	The risk or severity of CNS depression can be increased when Lamotrigine is combined with Cyamemazine.
Lasmiditan	The risk or severity of adverse effects can be increased when Lasmiditan is combined with Cyamemazine.
Lemborexant	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Lemborexant.
Levacetylmethadol	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Levacetylmethadol.
Levetiracetam	The risk or severity of CNS depression can be increased when Levetiracetam is combined with Cyamemazine.
Levobetaxolol	The serum concentration of Levobetaxolol can be increased when it is combined with Cyamemazine.
Levobupivacaine	The risk or severity of CNS depression can be increased when Levobupivacaine is combined with Cyamemazine.
Levocetirizine	The risk or severity of CNS depression can be increased when Levocetirizine is combined with Cyamemazine.
Levodopa	The risk or severity of CNS depression can be increased when Levodopa is combined with Cyamemazine.
Levomilnacipran	The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Cyamemazine.
Levorphanol	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Levorphanol.
Lidocaine	The risk or severity of CNS depression can be increased when Lidocaine is combined with Cyamemazine.
Lincomycin	Lincomycin may increase the neurotoxic activities of Cyamemazine.
Linezolid	The risk or severity of extrapyramidal symptoms can be increased when Linezolid is combined with Cyamemazine.
Lisdexamfetamine	Cyamemazine may decrease the stimulatory activities of Lisdexamfetamine.
Lisuride	The risk or severity of CNS depression can be increased when Lisuride is combined with Cyamemazine.
Lithium carbonate	Lithium carbonate may increase the neurotoxic activities of Cyamemazine.
Lithium citrate	Lithium citrate may increase the neurotoxic activities of Cyamemazine.
Lithium hydroxide	Lithium hydroxide may increase the neurotoxic activities of Cyamemazine.
Lofexidine	The therapeutic efficacy of Cyamemazine can be increased when used in combination with Lofexidine.
Lorazepam	The risk or severity of CNS depression can be increased when Lorazepam is combined with Cyamemazine.
Lorcaserin	The risk or severity of adverse effects can be increased when Lorcaserin is combined with Cyamemazine.
Lormetazepam	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Lormetazepam.
Lorpiprazole	The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Cyamemazine.
Loxapine	The risk or severity of CNS depression can be increased when Loxapine is combined with Cyamemazine.
Lumateperone	The risk or severity of adverse effects can be increased when Lumateperone is combined with Cyamemazine.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Cyamemazine.
Lurasidone	The risk or severity of CNS depression can be increased when Lurasidone is combined with Cyamemazine.
Magaldrate	Magaldrate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonate	Magnesium carbonate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxide	Magnesium hydroxide can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxide	Magnesium oxide can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium silicate	Magnesium silicate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium sulfate	The therapeutic efficacy of Cyamemazine can be increased when used in combination with Magnesium sulfate.
Magnesium trisilicate	Magnesium trisilicate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Maprotiline	The risk or severity of adverse effects can be increased when Maprotiline is combined with Cyamemazine.
Mazindol	The risk or severity of adverse effects can be increased when Mazindol is combined with Cyamemazine.
Mebutamate	The risk or severity of CNS depression can be increased when Mebutamate is combined with Cyamemazine.
Meclizine	The risk or severity of CNS depression can be increased when Meclizine is combined with Cyamemazine.
Medifoxamine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Medifoxamine.
Mefloquine	The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Cyamemazine.
Melatonin	The risk or severity of CNS depression can be increased when Melatonin is combined with Cyamemazine.
Meperidine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Meperidine.
Mephentermine	Cyamemazine may decrease the stimulatory activities of Mephentermine.
Mephenytoin	The risk or severity of CNS depression can be increased when Mephenytoin is combined with Cyamemazine.
Mepivacaine	The risk or severity of CNS depression can be increased when Mepivacaine is combined with Cyamemazine.
Meprobamate	The risk or severity of CNS depression can be increased when Meprobamate is combined with Cyamemazine.
Mepyramine	The risk or severity of CNS depression can be increased when Mepyramine is combined with Cyamemazine.
Mesoridazine	The risk or severity of CNS depression can be increased when Mesoridazine is combined with Cyamemazine.
Metamfetamine	Cyamemazine may decrease the stimulatory activities of Metamfetamine.
Metaxalone	The risk or severity of CNS depression can be increased when Metaxalone is combined with Cyamemazine.
Metergoline	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Metergoline.
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Cyamemazine.
Methocarbamol	The risk or severity of CNS depression can be increased when Methocarbamol is combined with Cyamemazine.
Methohexital	The risk or severity of CNS depression can be increased when Methohexital is combined with Cyamemazine.
Methotrimeprazine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane	The risk or severity of CNS depression can be increased when Methoxyflurane is combined with Cyamemazine.
Methoxyphenamine	Cyamemazine may decrease the stimulatory activities of Methoxyphenamine.
Methsuximide	The risk or severity of CNS depression can be increased when Methsuximide is combined with Cyamemazine.
Methylene blue	The risk or severity of extrapyramidal symptoms can be increased when Methylene blue is combined with Cyamemazine.
Methylphenidate	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Methylphenidate.
Methylphenobarbital	The risk or severity of CNS depression can be increased when Methylphenobarbital is combined with Cyamemazine.
Methyprylon	The risk or severity of CNS depression can be increased when Methyprylon is combined with Cyamemazine.
Methysergide	The risk or severity of CNS depression can be increased when Methysergide is combined with Cyamemazine.
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyamemazine.
Metocurine	The risk or severity of CNS depression can be increased when Metocurine is combined with Cyamemazine.
Metocurine iodide	The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Cyamemazine.
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Cyamemazine.
Metyrosine	The risk or severity of extrapyramidal symptoms and CNS depression can be increased when Metyrosine is combined with Cyamemazine.
Mianserin	The risk or severity of adverse effects can be increased when Mianserin is combined with Cyamemazine.
Midazolam	The risk or severity of sedation and CNS depression can be increased when Midazolam is combined with Cyamemazine.
Milnacipran	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Milnacipran.
Minaprine	The risk or severity of extrapyramidal symptoms can be increased when Minaprine is combined with Cyamemazine.
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Mirtazapine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mivacurium	The risk or severity of CNS depression can be increased when Mivacurium is combined with Cyamemazine.
Moclobemide	The risk or severity of extrapyramidal symptoms can be increased when Moclobemide is combined with Cyamemazine.
Molindone	The risk or severity of CNS depression can be increased when Molindone is combined with Cyamemazine.
Moricizine	The risk or severity of CNS depression can be increased when Moricizine is combined with Cyamemazine.
Morphine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Morphine.
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Cyamemazine.
Nalbuphine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Nalbuphine.
Naloxegol	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Naloxegol.
Naltrexone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Naltrexone.
Naphazoline	The risk or severity of CNS depression can be increased when Naphazoline is combined with Cyamemazine.
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Cyamemazine.
Naxitamab	Cyamemazine may increase the neurotoxic activities of Naxitamab.
Nebivolol	The serum concentration of Nebivolol can be increased when it is combined with Cyamemazine.
Nefazodone	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Nefazodone.
Neomycin	Neomycin may increase the neurotoxic activities of Cyamemazine.
Nialamide	The risk or severity of extrapyramidal symptoms can be increased when Nialamide is combined with Cyamemazine.
Nitrazepam	The risk or severity of CNS depression can be increased when Nitrazepam is combined with Cyamemazine.
Nitrous oxide	The risk or severity of CNS depression can be increased when Nitrous oxide is combined with Cyamemazine.
Nomifensine	The risk or severity of CNS depression can be increased when Nomifensine is combined with Cyamemazine.
Normethadone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Normethadone.
Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Cyamemazine.
Olanzapine	The risk or severity of CNS depression can be increased when Olanzapine is combined with Cyamemazine.
Oliceridine	The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Cyamemazine is combined with Oliceridine.
Ondansetron	The risk or severity of CNS depression can be increased when Ondansetron is combined with Cyamemazine.
Opium	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Opium.
Orphenadrine	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Oxazepam	The risk or severity of CNS depression can be increased when Oxazepam is combined with Cyamemazine.
Oxcarbazepine	The risk or severity of CNS depression can be increased when Oxcarbazepine is combined with Cyamemazine.
Oxitriptan	The risk or severity of CNS depression can be increased when Oxitriptan is combined with Cyamemazine.
Oxprenolol	The serum concentration of Oxprenolol can be increased when it is combined with Cyamemazine.
Oxybuprocaine	The risk or severity of CNS depression can be increased when Oxybuprocaine is combined with Cyamemazine.
Oxycodone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Oxycodone.
Oxymorphone	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Oxymorphone.
Paclitaxel	Paclitaxel may increase the neurotoxic activities of Cyamemazine.
Padeliporfin	Cyamemazine may increase the photosensitizing activities of Padeliporfin.
Paliperidone	The risk or severity of CNS depression can be increased when Paliperidone is combined with Cyamemazine.
Palonosetron	The risk or severity of CNS depression can be increased when Palonosetron is combined with Cyamemazine.
Pancuronium	The risk or severity of CNS depression can be increased when Pancuronium is combined with Cyamemazine.
Paraldehyde	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paramethadione	The risk or severity of CNS depression can be increased when Paramethadione is combined with Cyamemazine.
Pargyline	The risk or severity of extrapyramidal symptoms can be increased when Pargyline is combined with Cyamemazine.
Paroxetine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Paroxetine.
Penbutolol	The serum concentration of Penbutolol can be increased when it is combined with Cyamemazine.
Pentazocine	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Pentazocine.
Pentobarbital	The risk or severity of CNS depression can be increased when Pentobarbital is combined with Cyamemazine.
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Perazine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Perazine.
Pergolide	The risk or severity of CNS depression can be increased when Pergolide is combined with Cyamemazine.
Periciazine	The risk or severity of CNS depression can be increased when Periciazine is combined with Cyamemazine.
Perphenazine	The risk or severity of CNS depression can be increased when Perphenazine is combined with Cyamemazine.
Phenacemide	The risk or severity of CNS depression can be increased when Phenacemide is combined with Cyamemazine.
Phendimetrazine	Cyamemazine may decrease the stimulatory activities of Phendimetrazine.
Phenelzine	The risk or severity of extrapyramidal symptoms can be increased when Phenelzine is combined with Cyamemazine.
Phenobarbital	The risk or severity of CNS depression can be increased when Phenobarbital is combined with Cyamemazine.
Phensuximide	The risk or severity of CNS depression can be increased when Phensuximide is combined with Cyamemazine.
Phentermine	Cyamemazine may decrease the stimulatory activities of Phentermine.
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Cyamemazine.
Pimavanserin	Pimavanserin may increase the neurotoxic activities of Cyamemazine.
Pimozide	The risk or severity of CNS depression can be increased when Pimozide is combined with Cyamemazine.
Pindolol	The serum concentration of Pindolol can be increased when it is combined with Cyamemazine.
Pipecuronium	The risk or severity of CNS depression can be increased when Pipecuronium is combined with Cyamemazine.
Piperaquine	The risk or severity of QTc prolongation can be increased when Piperaquine is combined with Cyamemazine.
Pipotiazine	The risk or severity of CNS depression can be increased when Pipotiazine is combined with Cyamemazine.
Piritramide	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Piritramide.
Pizotifen	The risk or severity of CNS depression can be increased when Pizotifen is combined with Cyamemazine.
Polymyxin B	Cyamemazine may increase the neurotoxic activities of Polymyxin B.
Pomalidomide	The risk or severity of CNS depression can be increased when Pomalidomide is combined with Cyamemazine.
Porfimer sodium	Cyamemazine may increase the photosensitizing activities of Porfimer sodium.
Practolol	The serum concentration of Practolol can be increased when it is combined with Cyamemazine.
Pramipexole	Cyamemazine may increase the sedative activities of Pramipexole.
Pramocaine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Pramocaine.
Prazepam	The risk or severity of CNS depression can be increased when Prazepam is combined with Cyamemazine.
Pregabalin	The therapeutic efficacy of Cyamemazine can be increased when used in combination with Pregabalin.
Prilocaine	The risk or severity of CNS depression can be increased when Prilocaine is combined with Cyamemazine.
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Cyamemazine.
Primidone	The risk or severity of CNS depression can be increased when Primidone is combined with Cyamemazine.
Procaine	The risk or severity of extrapyramidal symptoms can be increased when Procaine is combined with Cyamemazine.
Procarbazine	The risk or severity of extrapyramidal symptoms can be increased when Procarbazine is combined with Cyamemazine.
Prochlorperazine	The risk or severity of CNS depression can be increased when Prochlorperazine is combined with Cyamemazine.
Proguanil	The risk or severity of QTc prolongation can be increased when Proguanil is combined with Cyamemazine.
Promazine	The risk or severity of CNS depression can be increased when Promazine is combined with Cyamemazine.
Promethazine	The risk or severity of adverse effects can be increased when Promethazine is combined with Cyamemazine.
Propafenone	The serum concentration of Propafenone can be increased when it is combined with Cyamemazine.
Propiomazine	The risk or severity of CNS depression can be increased when Propiomazine is combined with Cyamemazine.
Propofol	The risk or severity of CNS depression can be increased when Propofol is combined with Cyamemazine.
Propranolol	The serum concentration of Propranolol can be increased when it is combined with Cyamemazine.
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Cyamemazine.
Proxibarbal	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Proxibarbal.
Pseudoephedrine	Cyamemazine may decrease the stimulatory activities of Pseudoephedrine.
Pyrantel	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Pyrantel.
Pyrimethamine	The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Cyamemazine.
Quazepam	The risk or severity of CNS depression can be increased when Quazepam is combined with Cyamemazine.
Quetiapine	The risk or severity of CNS depression can be increased when Quetiapine is combined with Cyamemazine.
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Cyamemazine.
Quinidine	The risk or severity of QTc prolongation can be increased when Quinidine is combined with Cyamemazine.
Quinine	The risk or severity of QTc prolongation can be increased when Quinine is combined with Cyamemazine.
Quinupramine	The serum concentration of Quinupramine can be increased when it is combined with Cyamemazine.
Ramelteon	The risk or severity of CNS depression can be increased when Ramelteon is combined with Cyamemazine.
Rapacuronium	The risk or severity of CNS depression can be increased when Rapacuronium is combined with Cyamemazine.
Rasagiline	The risk or severity of extrapyramidal symptoms can be increased when Rasagiline is combined with Cyamemazine.
Reboxetine	The risk or severity of CNS depression can be increased when Reboxetine is combined with Cyamemazine.
Remifentanil	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Remifentanil.
Remimazolam	The risk or severity of sedation can be increased when Cyamemazine is combined with Remimazolam.
Remoxipride	The risk or severity of CNS depression can be increased when Remoxipride is combined with Cyamemazine.
Reserpine	The risk or severity of CNS depression can be increased when Reserpine is combined with Cyamemazine.
Riluzole	The risk or severity of CNS depression can be increased when Riluzole is combined with Cyamemazine.
Rimonabant	The risk or severity of adverse effects can be increased when Rimonabant is combined with Cyamemazine.
Risperidone	The risk or severity of CNS depression can be increased when Risperidone is combined with Cyamemazine.
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Cyamemazine.
Rocuronium	The risk or severity of CNS depression can be increased when Rocuronium is combined with Cyamemazine.
Ropeginterferon alfa-2b	The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Cyamemazine.
Ropinirole	Cyamemazine may increase the sedative activities of Ropinirole.
Ropivacaine	The risk or severity of CNS depression can be increased when Ropivacaine is combined with Cyamemazine.
Rotigotine	Cyamemazine may increase the sedative activities of Rotigotine.
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Cyamemazine.
Safinamide	The risk or severity of extrapyramidal symptoms can be increased when Safinamide is combined with Cyamemazine.
Samidorphan	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Samidorphan.
Scopolamine	The risk or severity of CNS depression can be increased when Scopolamine is combined with Cyamemazine.
Secobarbital	The risk or severity of CNS depression can be increased when Secobarbital is combined with Cyamemazine.
Selegiline	The risk or severity of extrapyramidal symptoms can be increased when Selegiline is combined with Cyamemazine.
Sertindole	The risk or severity of CNS depression can be increased when Sertindole is combined with Cyamemazine.
Sertraline	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Sertraline.
Sevoflurane	The risk or severity of CNS depression can be increased when Sevoflurane is combined with Cyamemazine.
Sibutramine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Sibutramine.
Sodium bicarbonate	Sodium bicarbonate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sodium citrate	Cyamemazine may increase the neurotoxic activities of Sodium citrate.
Sodium oxybate	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Solriamfetol	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Solriamfetol.
Sotalol	The serum concentration of Sotalol can be increased when it is combined with Cyamemazine.
St. John's Wort	The risk or severity of CNS depression can be increased when St. John's Wort is combined with Cyamemazine.
Stavudine	Stavudine may increase the neurotoxic activities of Cyamemazine.
Stiripentol	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Stiripentol.
Succinylcholine	The risk or severity of CNS depression can be increased when Succinylcholine is combined with Cyamemazine.
Sufentanil	The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Sufentanil.
Sulfadoxine	The risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Cyamemazine.
Sulpiride	Cyamemazine may increase the antipsychotic activities of Sulpiride.
Sulthiame	The risk or severity of CNS depression can be increased when Sulthiame is combined with Cyamemazine.
Sultopride	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Sultopride.
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyamemazine.
Suvorexant	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tafenoquine	The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Cyamemazine.
Talbutal	The risk or severity of CNS depression can be increased when Talbutal is combined with Cyamemazine.
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyamemazine.
Tasimelteon	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Tasimelteon.
Temazepam	The risk or severity of CNS depression can be increased when Temazepam is combined with Cyamemazine.
Teniposide	Teniposide may increase the neurotoxic activities of Cyamemazine.
Tetrabenazine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Tetrabenazine.
Tetracaine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Tetracaine.
Thalidomide	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal	The risk or severity of CNS depression can be increased when Thiamylal is combined with Cyamemazine.
Thiethylperazine	The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Cyamemazine.
Thiopental	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Thiopental.
Thioridazine	The risk or severity of CNS depression can be increased when Thioridazine is combined with Cyamemazine.
Thiothixene	The risk or severity of CNS depression can be increased when Thiothixene is combined with Cyamemazine.
Tiagabine	The risk or severity of CNS depression can be increased when Tiagabine is combined with Cyamemazine.
Timolol	The serum concentration of Timolol can be increased when it is combined with Cyamemazine.
Tizanidine	The risk or severity of CNS depression can be increased when Tizanidine is combined with Cyamemazine.
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Cyamemazine.
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Cyamemazine.
Tolcapone	The risk or severity of CNS depression can be increased when Tolcapone is combined with Cyamemazine.
Topiramate	The risk or severity of CNS depression can be increased when Topiramate is combined with Cyamemazine.
Tramadol	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Tramadol.
Tranylcypromine	The risk or severity of extrapyramidal symptoms can be increased when Tranylcypromine is combined with Cyamemazine.
Trazodone	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Trazodone.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Cyamemazine.
Triazolam	The risk or severity of CNS depression can be increased when Triazolam is combined with Cyamemazine.
Trichloroethylene	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Trichloroethylene.
Triclofos	The risk or severity of CNS depression can be increased when Triclofos is combined with Cyamemazine.
Trifluoperazine	The risk or severity of CNS depression can be increased when Trifluoperazine is combined with Cyamemazine.
Triflupromazine	The risk or severity of CNS depression can be increased when Triflupromazine is combined with Cyamemazine.
Trimethadione	The risk or severity of CNS depression can be increased when Trimethadione is combined with Cyamemazine.
Trimethobenzamide	The risk or severity of CNS depression can be increased when Trimethobenzamide is combined with Cyamemazine.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Cyamemazine.
Triprolidine	The risk or severity of CNS depression can be increased when Triprolidine is combined with Cyamemazine.
Tropisetron	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Tropisetron.
Tryptophan	The risk or severity of CNS depression can be increased when Tryptophan is combined with Cyamemazine.
Tubocurarine	The risk or severity of CNS depression can be increased when Tubocurarine is combined with Cyamemazine.
Urethane	The risk or severity of CNS depression can be increased when Urethane is combined with Cyamemazine.
Valproate bismuth	Cyamemazine may increase the neurotoxic activities of Valproate bismuth.
Valproic acid	The risk or severity of CNS depression can be increased when Valproic acid is combined with Cyamemazine.
Vecuronium	The risk or severity of CNS depression can be increased when Vecuronium is combined with Cyamemazine.
Venlafaxine	The risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyamemazine.
Verteporfin	Cyamemazine may increase the photosensitizing activities of Verteporfin.
Vigabatrin	The risk or severity of CNS depression can be increased when Vigabatrin is combined with Cyamemazine.
Vilazodone	The risk or severity of adverse effects can be increased when Vilazodone is combined with Cyamemazine.
Viloxazine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Viloxazine.
Vincristine	Vincristine may increase the neurotoxic activities of Cyamemazine.
Vinorelbine	Vinorelbine may increase the neurotoxic activities of Cyamemazine.
Viomycin	Viomycin may increase the neurotoxic activities of Cyamemazine.
Vortioxetine	The risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyamemazine.
Yohimbine	The therapeutic efficacy of Cyamemazine can be increased when used in combination with Yohimbine.
Zaleplon	The risk or severity of CNS depression can be increased when Zaleplon is combined with Cyamemazine.
Ziconotide	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Ziconotide.
Zimelidine	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Zimelidine.
Ziprasidone	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Ziprasidone.
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyamemazine.
Zolpidem	Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide	The risk or severity of CNS depression can be increased when Zonisamide is combined with Cyamemazine.
Zopiclone	The risk or severity of adverse effects can be increased when Cyamemazine is combined with Zopiclone.
Zotepine	The risk or severity of CNS depression can be increased when Cyamemazine is combined with Zotepine.
Zuclopenthixol	The risk or severity of CNS depression can be increased when Zuclopenthixol is combined with Cyamemazine.
Zuranolone	The risk or severity of CNS depression can be increased when Zuranolone is combined with Cyamemazine.

Food Interactions

Not Available

Products

: Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands: Tercian (Sanofi-Aventis)

Chemical Identifiers

UNII: A2JGV5CNU4
CAS number: 3546-03-0
InChI Key: SLFGIOIONGJGRT-UHFFFAOYSA-N
InChI: InChI=1S/C19H21N3S/c1-14(12-21(2)3)13-22-16-6-4-5-7-18(16)23-19-9-8-15(11-20)10-17(19)22/h4-10,14H,12-13H2,1-3H3
IUPAC Name: 10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile
SMILES: CC(CN(C)C)CN1C2=CC=CC=C2SC2=C1C=C(C=C2)C#N

References

Synthesis Reference

U.S. Patent 2,877,224.

General References

Not Available

External Links

KEGG Drug: D07307
PubChem Compound: 62865
PubChem Substance: 310264961
ChemSpider: 56597
BindingDB: 86057
RxNav: 21877
ChEBI: 135379
ChEMBL: CHEMBL2104153
Drugs.com: Drugs.com Drug Page
Wikipedia: Cyamemazine

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count

Pharmacoeconomics

Manufacturers: Not Available
Packagers: Not Available
Dosage Forms: Not Available
Prices: Not Available
Patents: Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	204-205	U.S. Patent 2,877,224.

Predicted Properties

Property	Value	Source
Water Solubility	0.029 mg/mL	ALOGPS
logP	4.28	ALOGPS
logP	4.27	Chemaxon
logS	-4	ALOGPS
pKa (Strongest Basic)	9.42	Chemaxon
Physiological Charge	1	Chemaxon
Hydrogen Acceptor Count	3	Chemaxon
Hydrogen Donor Count	0	Chemaxon
Polar Surface Area	30.27 Å²	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	99.09 m³·mol^-1	Chemaxon
Polarizability	36.48 Å³	Chemaxon
Number of Rings	3	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	Yes	Chemaxon
Veber's Rule	Yes	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	splash10-052r-4091000000-8fd4f49543d5acc4171d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0fk9-0809000000-e9a47ba9e9b612c317f0
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00di-0029000000-688c415606fcea11bb52
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00di-0029000000-bace050610190a6af660
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-0q29-9355000000-66285b2e31caa1879c98
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-00dr-0190000000-0d53fef3947fb7c85f1c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-056r-5290000000-0730f877de6790187b95
Predicted 1H NMR Spectrum	1D NMR	Not Applicable
Predicted 13C NMR Spectrum	1D NMR	Not Applicable

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å²)	Source type	Source
[M-H]-	167.3835	predicted	DeepCCS 1.0 (2019)
[M+H]+	169.7415	predicted	DeepCCS 1.0 (2019)
[M+Na]+	176.07875	predicted	DeepCCS 1.0 (2019)

Drug created at June 17, 2014 16:28 / Updated at February 21, 2021 18:52

Cyamemazine

Identification

Structure for Cyamemazine (DB09000)

Pharmacology

Interactions

Products

Categories

Chemical Identifiers

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Collision Cross Sections (CCS)